The T-cell receptor alpha constant (TRAC) is a crucial component of the T-cell receptor (TCR) complex, a heterodimeric protein found on the surface of T lymphocytes. It plays an essential role in the adaptive immune response by facilitating the recognition of peptide-major histocompatibility (MHC) complexes presented by antigen-presenting cells. Upon binding to these complexes, the TRAC, as part of the TCR, initiates a complex intracellular signaling cascade involving proteins like LCK, ZAP70, and LAT, ultimately leading to T cell activation, growth, and differentiation.
Dysfunction of the TRAC gene can lead to severe primary immunodeficiency disorders, such as Immunodeficiency 7 (IMD7), characterized by a lack of functional TCRαβ+ T cells and increased susceptibility to infections and immune dysregulation. While not a direct antigen-binding site, the TRAC region is vital for the structural integrity and proper assembly of the TCR. In therapeutic contexts, particularly in cancer immunotherapy, the TRAC locus is a target for engineering T cells. Strategies like TCR-engineered T cells (TCR-T therapy) and HLA-independent T-cell (HIT) receptors involve modifying or inserting genes into the TRAC locus to enhance tumor recognition and cytotoxic activity. However, these approaches face challenges such as off-target toxicity, undesired mixed dimer formation with endogenous TCRs, and HLA restriction, necessitating careful design and safety assessments.
Forms part of the T-cell receptor (TCR) complexEssential for immune response and present on T lymphocytesRecognizes peptide-major histocompatibility (MHC) complexes displayed by antigen-presenting cells (APC)Initiates TCR-CD3 clustering and intracellular signaling pathways (LCK, ZAP70, LAT, MAPK, NF-kB) leading to T cell growth and differentiationCrucial for T cell signaling and functionContributes to the structural integrity and stability of the TCRInvolved in the generation of the T cell repertoire in the thymus
03
Disease associations
Immunodeficiency 7 (IMD7)Immunodeficiency 14Cancer (as a target for immunotherapy)Inflammatory Bowel Disease (IBD)
04
Safety considerations
Off-target reactivity and "on-target off-tumor" toxicity, where engineered TCRs may recognize unintended targets on healthy tissues, leading to autoimmune reactions.Undesired mixed dimer formation between introduced and endogenous TCR chains, potentially leading to autoreactive T cells or reduced therapeutic efficacy.HLA restriction, which limits the applicability of many TCR therapies to specific patient populations based on their HLA type.Potential for cytokine-related toxicities and T cell exhaustion, which are challenges associated with T-cell based immunotherapies.
05
Interacting drugs
TCR-engineered T cells (TCR-T therapy)
4 more in the full profile.
06
Biomarkers
TCR sequences for identifying antigen-specific T cells in immune responses, such as in Type 1 Diabetes.Specific TCR alpha/beta pairs for evaluating and quantifying infused T cell products in cell therapy.HLA typing for patient selection in HLA-dependent TCR T-cell therapy clinical trials.Tumor antigen expression (protein or mRNA) in tumor tissue for TCR T-cell therapies targeting cancer-testis antigens (CTAs).TCR alpha chain clonotypes, particularly islet antigen-specific ones, as potential biomarkers for Type 1 Diabetes.
Beyond the preview
Go deeper on T-cell receptor alpha constant (TRAC).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Drug pipeline
Explore the programs pursuing this target and their development progress.
Drug candidates
Developers
Development stage
Clinical trials
Follow the clinical studies evaluating therapies directed at this target.
Trial design
Status
Readouts
Competitive landscape
Compare approaches across drug candidates, modalities, and indications.
Programs
Modalities
Indications
Literature & evidence
Investigate the research and source evidence behind target biology and development.
Publications
Sources
Analysis
Patents
Explore patent activity around therapies and technologies addressing this target.
Patents
Assignees
Technologies
Research & analysis
Connect target biology, drug development, and emerging evidence in your research.
Biology
Development news
Analysis
Bring the full picture into focus.
See how Gosset can support your research on T-cell receptor alpha constant (TRAC).